ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconIcon FacebookIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerIcon Opinion QuotePositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Nikkei Markets

Fosun Pharma To Buy Out Other Shareholders In Taiwan-Based Henlix Biotech

By Carrie Chen
Nikkei Markets
HONG KONG (Nov 02) -- Shanghai Fosun Pharmaceutical (Group), a company controlled by Chinese conglomerate Fosun International, said a unit has agreed to acquire the 69.25% stake it doesn't already own in Taiwan-based biopharmaceutical company Henlix Biotech for up to $98 million.

The company's unit Shanghai Henlius will buy out other corporate and individual shareholders and make Henlix a wholly-owned subsidiary, Fosun Pharma said in a filing to the Hong Kong stock exchange on Thursday.

The agreement is subject to approvals from authorities in Taiwan and China.

?
- By Carrie Chen; Carrie.Chen@NikkeiNewsrise.com; +852 39605153
- Edited By V.Phani Kumar
- Send Feedback to feedback@NikkeiNewsRise.com
- Copyright (c) 2017 Nikkei NewsRise Asia Pte Ltd.

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

Get unlimited access
NAR site on phone, device, tablet

{{sentenceStarter}} {{numberReadArticles}} free article{{numberReadArticles-plural}} this month

Stay ahead with our exclusives on Asia; the most dynamic market in the world.

Benefit from in-depth journalism from trusted experts within Asia itself.

Try 3 months for $9

Offer ends September 30th

Your trial period has expired

You need a subscription to...

See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

See all offers
NAR on print phone, device, and tablet media